Article

Computationally Selected Multivalent HIV-1 Subtype C Vaccine Protects Against Heterologous SHIV Challenge

2024-12-18

Abstract excerpt

<h4>Background: </h4> The RV144 trial in Thailand is the only HIV-1 vaccine efficacy trial to date to demonstrate any efficacy. Genetic signatures suggested antibodies targeting the variable loop 2 (V2) of HIV-1 Envelope played an important protective role. The ALVAC prime and protein boost follow-up trial in southern Africa (HVTN702) failed to show any efficacy. One hypothesis for this is the greater diversity of...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 13d571f4-016c-5b97-a188-962f3b316b09
DOI: 10.20944/preprints202412.1501.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Computationally Selected Multivalent HIV-1 Subtype C Vaccine Protects Against Heterologous SHIV ChallengeDOI 10.20944/preprints202412.1501.v1Read

Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge.Semantic proximity Read

R5 Clade C SHIV Strains with Tier 1 or 2 Neutralization Sensitivity: Tools to Dissect Env Evolution and to Develop AIDS Vaccines in Primate ModelsSemantic proximity Read

Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challengeSemantic proximity Read

Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge.Semantic proximity Read

Viral evolution in macaques coinfected with CCR5- and CXCR4-tropic SHIVs in the presence or absence of vaccine-elicited anti-CCR5 SHIV neutralizing antibodies.Semantic proximity Read

New SHIVs and Improved Design Strategy for Modeling HIV-1 Transmission, Immunopathogenesis, Prevention and CureSemantic proximity Read

A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection.Semantic proximity Read

Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes.Semantic proximity Read

Protective Efficacy of a Global HIV-1 Mosaic Vaccine against Heterologous SHIV Challenges in Rhesus MonkeysSemantic proximity Read

CHIKV mRNA vaccines encoding conserved structural/envelope proteins confer broad cross-lineage protection against infectionSemantic proximity Read

Microarray Profiling of Antibody Responses against Simian-Human Immunodeficiency Virus: Postchallenge Convergence of Reactivities Independent of Host Histocompatibility Type and Vaccine RegimenSemantic proximity Read

Generation and Evaluation of Clade C Simian-Human Immunodeficiency Virus Challenge StocksSemantic proximity Read